The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Rebster I’m sure it was the formulation issues with SDC-1801 not Covid when the pandemic was ongoing Tim said in the summer of 2020 in a video and I’m sure in an RNS said that covid was not effecting the business, I think it was later into the pandemic that it was admitted it was effecting the business, and I’ve followed the pre-clinical development for some time, the timelines have without a doubt with or without covid has slipped time after time!
For all the newer holders of SAR who are underwhelmed by the tone of the RNS.
SAR's RNS's are always extremely matter of fact and concise. Unlike most other AIM companies they do not use hyperboles or words that are emotive. They are factual and nothing else. This is their style, on first reading RNS can appear pretty flat, however once you concentrate on the data presented you can very quickly realise the huge positives.
For me, the stand out bit of info is in respect of capsules. This could and should be a game changer for SAR. (And potentially for society in general). Not only for COVID but for many many other treatments as well.
Overall a better than expected RNS.
AIMHO
Elcap
He’s not invested here Rebster - and never was. But loves to taunt the board at every opportunity.
Fadec
Your point is?
Im sure you are aware there was/is a global pandemic that shut the world down pretty much for the whole of 2020 and half of 2021...so I'm not sure what point you are trying to make re timelines...
Delays were almost a given considering the 18month shutdown...
That is massively promising- they have now indicated that we are going to use the HNWI's money to go into clinic, so my take is 1802 will follow suit.
The price just doubled if not trebled since we get the patent in force tomorrow for 1802 which is already world-wide patent protected with no tox or mtd and no competition in the cancer Tyk2 immuno market.
Many happy returns chaps- the price is what it is as you expect nothing goes up in a straight line but nothing negative today whatsoever.
Thanks Fadec. I looked only at the Results rather then the AGM reps.
As I said, pose the question poss. with the additional comment that continual extension of timelines causes unrest and a wobble in confidence.
18th December 2018
Start clinical trials both in 2020
https://www.lse.co.uk/rns/SAR/agm-statement-450qg773hfl60kj.html
13th June 2019
Start clinical trials both in 2020
https://www.lse.co.uk/rns/SAR/portfolio-update-2qe2t4u476hh8bb.html
27th August 2019
Start clinical trials both in late 2020
https://www.lse.co.uk/rns/SAR/trading-statement-w5yp0m5v56rommk.html
17 December 2019
Start clinical trials both in late 2020
https://www.lse.co.uk/rns/SAR/agm-statement-m6bpjk5kfj7cge2.html
https://imgur.com/a/sB9EME0
Fadec.
Having had a quick look at the last three Ann. Reps. can't see any mention of your 2019/20 timescales but maybe just missed them.
It’s always the same Ndr50, I can’t remember exactly but it was supposed too be 2019/2020 for end of pre-clinical and CTA but each time it gets near it gets pushed year after year!
Very upbeat and a good update overall.
It doesn’t matter where sp goes in the short term. The opportunity has been laid out for all to see.
Hold or buy.
Further delays and no definite timescale when 1801 will be application Covid. Disappointed with the general tone.
Dr Tim Mitchell, CEO of Sareum, commented:
"Sareum continues to advance the preclinical development of its proprietary dual TYK2/JAK1 inhibitor programmes. We are close to completing the preclinical development of SDC-1801 with the aim of starting the clinical development of this novel compound in the second half of 2022. This is clearly a very important milestone for the Company. In addition, the early preclinical results we have seen with SDC-1801 in our Covid-19 programme suggest that it may have potential to address the hyper-inflammatory response that some patients experience, and we are looking at the next steps to advance development in this indication. We are particularly pleased to have raised substantial additional funding that will be deployed to advance these programmes into clinical development and build a robust data package that will add momentum to our ongoing partnering activities for these exciting and differentiated assets.
"Furthermore, the possibility that clinical combination studies of SRA737 could be initiated by Sierra in the first half of 2022 is very encouraging and would represent a significant advance in the development of the SRA737 programme. We look forward to further updates on the clinical development of this candidate as the programme progresses."